Short Interest in Prenetics Global Limited (NASDAQ:PRE) Declines By 20.8%

Prenetics Global Limited (NASDAQ:PRE - Get Free Report) saw a significant decline in short interest during the month of May. As of May 15th, there was short interest totalling 23,600 shares, a decline of 20.8% from the April 30th total of 29,800 shares. Based on an average daily trading volume, of 15,900 shares, the days-to-cover ratio is currently 1.5 days. Currently, 0.3% of the shares of the company are short sold.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Prenetics Global stock. Nomura Holdings Inc. raised its holdings in Prenetics Global Limited (NASDAQ:PRE - Free Report) by 3.3% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 333,528 shares of the company's stock after buying an additional 10,576 shares during the quarter. Nomura Holdings Inc. owned approximately 2.73% of Prenetics Global worth $1,307,000 at the end of the most recent quarter. 25.01% of the stock is currently owned by hedge funds and other institutional investors.

Prenetics Global Stock Down 8.8%

Shares of NASDAQ PRE traded down $0.79 during mid-day trading on Thursday, hitting $8.21. 27,801 shares of the company were exchanged, compared to its average volume of 19,475. Prenetics Global has a 1-year low of $3.09 and a 1-year high of $11.99. The stock has a 50 day simple moving average of $5.85 and a 200-day simple moving average of $5.38. The firm has a market cap of $100.20 million, a price-to-earnings ratio of -2.06 and a beta of 0.17.

About Prenetics Global

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.